Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer

Tumor Biology

Volumn 28, Issue 5, 2007, Pages 280-289

  Sillanpaa S ^a   Anttila, M ^a,b   Suhonen, K ^a   Hamalainen K ^a,b   Turpeenniemi Hujanen, T ^c   Puistola, U ^c   Tammi, M ^a   Sironen, R ^a,b   Saarikoski, S ^b   Kosma, V M ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Extracellular matrix metalloproteinase inducer; Hyaluronan; Matrix metalloproteinase 2; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CD147 ANTIGEN; GELATINASE A; HYALURONIC ACID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; OUTCOME ASSESSMENT; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

EID: 36448962792     PISSN: 10104283     EISSN: None     Source Type: Journal    
DOI: 10.1159/000110426     Document Type: Article

References (30)

1. Curran S, Murray GI: Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer 2000;36:1621-1630.
2. Campo E, Merino MJ, Tavassoli FA, Charonis AS, Stetler-Stevenson WG, Liotta LA: Evaluation of basement membrane components and the 72 kDa type IV collagenase in serous tumors of the ovary. Am J Surg Pathol 1992;16:500-507.
3. De Nictolis M, Garbisa S, Lucarini G, Goteri G, Masiero L, Ciavattini A, et al: 72-kilodalton type IV collagenase, type IV collagen, and ki 67 antigen in serous tumors or the ovary: a clinicopathologic, immunohistochemical, and serological study. Int J Gynecol Pathol 1996;15:102-109.
4. Garzetti GG, Ciavattini A, Lucarini G, Goteri G, de Nictolis M, Garbisa S, et al: Tissue and serum metalloproteinase (MMP-2) expression in advanced ovarian serous cystoadenocarcinomas: clinical and prognostic implications. Anticancer Res 1995;15:2799-2804.
5. Schmalfeldt B, Prechtel D, Harting K, Spathe K, Rutke S, Konik E, et al: Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer. Clin Cancer Res 2001;7:2396-2404.
6. Westerlund A, Apaja-Sarkkinen M, Hoyhtya M, Puistola U, Turpeenniemi-Hujanen T: Gelatinase A-immunoreactive protein in ovarian lesions - prognostic value in epithelial ovarian cancer. Gynecol Oncol 1999;75:91-98.
7. Torng PL, Mao TL, Chan WY, Huang SC, Lin CT: Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression. Gynecol Oncol 2004;92:559-567.
8. Kamat AA, Fletcher M, Gruman LM, Mueller P, Lopez A, Landen CN Jr, et al: The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res 2006;12:1707-1714.
9. Toole BP: EMMPRIN (CD147), a cell surface regulator of matrix metalloproteinase production and function. Curr Top Dev Biol 2003;54:371-389.
10. Kataoka H, DeCastro R, Zucker S, Biswas C: Tumor cell-derived collagenase-stimulatory factor increases expression of interstitial collagenase, stromelysin, and 72-kDa gelatinase. Cancer Res 1993;53:3154-3158.
11. Davidson B, Goldberg I, Berner A, Kristensen GB, Reich R: EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Clin Exp Metastasis 2003;20:161-169.
12. Zhang Y, Thant AA, Machida K, Ichigotani Y, Naito Y, Hiraiwa Y, et al: Hyaluronan-CD44s signaling regulates matrix metalloproteinase-2 secretion in a human lung carcinoma cell line QG90. Cancer Res 2002;62:3962-3965.
13. Isnard N, Legeais JM, Renard G, Robert L: Effect of hyaluronan on MMP expression and activation. Cell Biol Int 2001;25:735-739.
14. Anttila MA, Tammi RH, Tammi MI, Syrjanen KJ, Saarikoski SV, Kosma VM: High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer. Cancer Res 2000;60:150-155.
15. Marieb EA, Zoltan-Jones A, Li R, Misra S, Ghatak S, Cao J, et al: EMMPRIN promotes anchorage-independent growth in human mammary carcinoma cells by stimulating hyaluronan production. Cancer Res 2004;64:1229-1232.
16. Serov SF, Scully RE (eds): International Histological Classification of Tumors. Geneva, World Health Organization, 1973, vol 9, pp 17-21.
17. Simon R, Altman DG: Statistical aspects of prognostic factor studies in oncology. Br J Cancer 1994;69:979-985.
18. Sun J, Hemler ME: Regulation of MMP-1 and MMP-2 production through CD147/extracellular matrix metalloproteinase inducer interactions. Cancer Res 2001;61:2276-2281.
19. Caudroy S, Polette M, Nawrocki-Raby B, Cao J, Toole BP, Zucker S, et al: EMMPRIN-mediated MMP regulation in tumor and endothelial cells. Clin Exp Metastasis 2002;19:697-702.
20. Misra S, Ghatak S, Zoltan-Jones A, Toole BP: Regulation of multidrug resistance in cancer cells by hyaluronan. J Biol Chem 2003;278:25285-25288.
21. Reimers N, Zafrakas K, Assmann V, Egen C, Riethdorf L, Riethdorf S, et al: Expression of extracellular matrix metalloproteases inducer on micrometastatic and primary mammary carcinoma cells. Clin Cancer Res 2004;10:3422-3428.
22. van den Oord JJ, Paemen L, Opdenakker G, de Wolf-Peeters C: Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am J Pathol 1997;151:665-670.
23. Jin JS, Yao CW, Loh SH, Cheng MF, Hsieh DS, Bai CY: Increasing expression of extracellular matrix metalloprotease inducer in ovary tumors: tissue microarray analysis of immunostaining score with clinicopathological parameters. Int J Gynecol Pathol 2006;25:140-146.
24. Afzal S, Lalani E, Foulkes WD, Boyce B, Tickle S, Cardillo MR, et al: Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression and synthetic matrix metalloproteinase-2 inhibitor binding in ovarian carcinomas and tumor cell lines. Lab Invest 1996;74:406-421.
25. Wu X, Li H, Kang L, Li L, Wang W, Shan B: Activated matrix metalloproteinase-2 - a potential marker of prognosis for epithelial ovarian cancer. Gynecol Oncol 2002;84:126-134.
26. Jin JS, Hsieh DS, Lin YF, Wang JY, Sheu LF, Lee WH: Increasing expression of extracellular matrix metalloprotease inducer in renal cell carcinoma: tissue microarray analysis of immunostaining score with clinicopathological parameters. Int J Urol 2006;13:573-580.
27. Kuittinen O, Savolainen ER, Koistinen P, Turpeenniemi-Hujanen T: Gelatinase A and B (MMP-2, MMP-9) in leukaemia MMP-2 may indicate a good prognosis in AML. Anticancer Res 1999;19:4395-4400.
28. Kuittinen O, Soini Y, Turpeenniemi-Hujanen T: Diverse role of MMP-2 and MMP-9 in the clinicopathological behavior of Hodgkin's lymphoma. Eur J Haematol 2002;69:205-212.
29. Rauvala M, Puistola U, Turpeenniemi-Hujanen T: Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor. Gynecol Oncol 2005;99:656-663.
30. Sillanpaa S, Anttila M, Voutilainen K, Ropponen K, Turpeenniemi-Hujanen T, Puistola U, et al: Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer. Gynecol Oncol 2007;104:296-303.